CompletedPhase 4

A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.

United States18 participantsStarted 2024-07-01

Plain-language summary

This pilot study is proposing a novel approach to directly target intestinal oxalate absorption with the drug Tenapanor, which was recently FDA-approved for treating hyperphosphatemia in patients with chronic kidney disease. Tenapanor works by blocking paracellular phosphate absorption by the intestine, but the underlying mechanisms have not been clearly defined. Since phosphate and oxalate ions are absorbed through the same paracellular pathway, and are of similar size and charge, Tenapanor is hypothesized to also reduce dietary oxalate absorption and consequently lower urinary oxalate excretion.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Normal, healthy adult volunteers Exclusion Criteria: * Personal history of kidney stones * Pregnant or nursing * Recurrent urinary tract infections * Lithogenic urine chemistry at baseline (oxalate \> 45 mg/24 h, urine calcium \> 300 mg/24 h) * Chronic kidney disease (eGFR \< 90 mL/min/1.73m2) * Personal history of GI disease, GI obstruction, or GI surgery * Chronic diarrhea * Intestinal inflammation (Fecal calprotectin \> 120 mcg/g) * Drugs which are substrates of OATP2B1 (e.g. enalapril) * Chronic use of sodium polystyrene sulfonate, angiotensin-converting enzyme inhibitors, diuretics, antacids, alkali treatment, or carbonic anhydrase inhibitors.

What they're measuring

24-h urine oxalate

Timeframe: Two 24-h urine on days 4 and 5 of each arm

Trial details

NCT IDNCT06481150

SponsorUniversity of Texas Southwestern Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-09-14

View on ClinicalTrials.gov More Hyperoxaluria trials